Organigram Holdings (OGI) Stock Analysis — October 2026
Executive Summary
Organigram Holdings (NASDAQ: OGI) is a licensed producer (lp) company currently priced at $0.94 per share with a market capitalization of $131.3M. The stock trades on the NASDAQ exchange in the Canadian market, and is positioned as a small-cap player within the cannabis sector.
Key Takeaways
Organigram Holdings has a market cap of $131.3M, making it a small-cap cannabis company listed on the NASDAQ.
At $0.94, the stock trades at 6% of its 52-week range ($0.85 – $2.24). Trading near yearly lows could present value for contrarian investors.
Organigram Holdings Company Overview
Organigram Holdings (NASDAQ: OGI) is a licensed cannabis producer (LP) currently trading at $0.94 per share with a market capitalization of $131.3M. The stock declined +0.43% in the most recent trading session on volume of 447.6K shares. Organigram Holdings is headquartered in Canada and employs approximately 1,139 people. As a participant in the licensed producer (lp) segment, the company operates within one of the most dynamic and rapidly evolving sectors of the North American economy.
Trailing twelve-month (TTM) revenue for Organigram Holdings is not reported in our data. Revenue trends in the cannabis industry are closely watched by analysts, as the sector continues to navigate pricing compression, oversupply dynamics in certain markets, and the ongoing burden of IRS Section 280E, which prevents cannabis businesses from deducting ordinary business expenses at the federal level.
Financial Analysis
Trailing twelve-month revenue for Organigram Holdings is not reported in our data.
Revenue momentum is a critical metric for cannabis companies, as the industry continues to evolve through shifts in consumer demand, regulatory changes, and competitive dynamics. Year-over-year revenue growth for Organigram Holdings is not reported in our data. The cannabis industry's profitability dynamics are heavily influenced by IRS Section 280E, which prevents plant-touching operators from deducting ordinary business expenses for federal income tax purposes, effectively creating tax rates that can exceed 70% of gross profit.
Valuation Analysis
A price-to-sales (P/S) ratio for Organigram Holdings is not available in our data. Cannabis stock valuations have compressed significantly from their 2021 highs, and current multiples reflect a more mature market environment where investors demand clear paths to profitability. For context, the broader LP sector contains 18 publicly traded companies tracked by Cannabismarketcap, and Organigram Holdings's valuation should be considered within the context of its specific growth profile and competitive positioning.
Balance Sheet Deep Dive
Cash and debt figures for Organigram Holdings are not reported in our data. Access to capital remains a persistent challenge for cannabis companies, particularly plant-touching operators that are excluded from traditional banking services and institutional lending. Many cannabis companies have turned to sale-leaseback transactions, private placements, and at-the-market (ATM) equity offerings to fund operations. Organigram Holdings's balance sheet should be evaluated with these industry-specific constraints in mind.
Cash and total debt for Organigram Holdings are not reported in our data, so we cannot assess its net cash or net debt position.
The company's annual share dilution rate is not reported in our data. With 136.3M shares currently outstanding, any additional equity issuance directly impacts per-share metrics including earnings per share, book value per share, and ownership percentage.
Licensed Producer (LP) Sector Context
Within the Licensed Producer (LP) sector, Organigram Holdings ranks #9 out of 18 companies by market capitalization, commanding a 3.5% share of the sector's total market cap of $3.70B. Licensed Producers are cannabis companies authorized by Health Canada to cultivate and sell cannabis. LPs were the primary vehicle for Canada's legal recreational market, which launched in October 2018, and many have expanded internationally. The largest company in the sector by market cap is Cronos Group (CRON) at $1.27B, followed by Tilray Brands (TLRY) at $440.4M.
Trailing twelve-month revenue for Organigram Holdings is not reported in our data, so it is not ranked by revenue. The sector's top revenue generator is Tilray Brands at $963.1M.
Organigram Holdings occupies a mid-tier position within the Licensed Producer (LP) sector. The company's market capitalization of $131.3M reflects the market's assessment of its growth potential and risk profile relative to the 17 other tracked peers. Investors should evaluate Organigram Holdings alongside its direct sector competitors to understand relative value and operational momentum.
Historical Price Performance
Organigram Holdings (OGI) currently trades at $0.94, which places the stock at approximately 6% of its 52-week trading range. Over the past twelve months, OGI has traded as high as $2.24 and as low as $0.85, representing a 162.6% spread between the yearly high and low. The current price sits 58.2% below the 52-week high and 9.8% above the 52-week low. This range provides important context for understanding the stock's recent volatility and where current levels fall within the broader price history.
In the most recent trading session, OGI fell +0.43% from a previous close of $0.94 to $0.94, on volume of 447.6K shares. This negative session is within the range of normal daily fluctuations for cannabis stocks, which tend to exhibit higher volatility than the broader equity market. The stock has 136,329,492 shares outstanding, giving it a fully diluted market capitalization that investors should factor into their analysis alongside the current $131.3M market cap figure.
Cannabis stocks have historically exhibited significant price volatility driven by regulatory developments, earnings surprises, and shifts in market sentiment toward the sector. OGI is trading in the lower portion of its 52-week range, which could represent a value opportunity for contrarian investors, or may reflect deteriorating fundamentals that warrant caution. Historical price levels should be considered alongside fundamental data — including revenue trends, margin improvement, and balance sheet health — to form a complete investment thesis.
Investment Thesis
A balanced framework for evaluating Organigram Holdings (OGI) as a potential investment, considering both the upside catalysts and downside risks based on the company's current financial data and industry positioning.
Revenue stabilization and potential for operational improvements could reignite top-line growth. Even modest gains in market share or pricing power could meaningfully impact the company's financial trajectory and investor sentiment toward OGI.
Potential for margin recovery as the cannabis market matures and pricing stabilizes. Regulatory reform — particularly the rescheduling of cannabis and elimination of Section 280E tax burdens — could dramatically improve the gross margin profile for Organigram Holdings and the broader industry.
Federal cannabis reform — including potential rescheduling, banking access via the SAFE Banking Act, or eventual descheduling — would be a transformative catalyst for Organigram Holdings and the entire cannabis sector. Any legislative progress could unlock institutional capital flows, improve banking access, and eliminate the Section 280E tax burden that suppresses profitability industry-wide.
Intensifying competition from both legal operators and the persistent illicit market could pressure Organigram Holdings's revenue growth and margins. The cannabis industry remains highly fragmented, and market share gains are becoming increasingly difficult as more states award licenses and new competitors enter the market.
Cannabis companies continue to face restricted access to traditional banking, institutional capital, and federal bankruptcy protections. These structural disadvantages increase the cost of capital and limit Organigram Holdings's financial flexibility compared to companies in federally legal industries, creating an uneven competitive landscape.
Regulatory uncertainty remains the single largest risk for Organigram Holdings and all cannabis investments. Federal prohibition in the United States creates ongoing challenges including Section 280E tax burdens, limited interstate commerce, and the risk of enforcement actions. State-level regulatory changes, licensing moratoriums, and social equity requirements add additional layers of unpredictability that can materially impact the company's operations and growth plans.
Risk Factors
Key risks that investors should consider before investing in Organigram Holdings (OGI). This is not an exhaustive list, and investors should conduct their own due diligence.
Regulatory & Legal Risk
Cannabis remains a Schedule I controlled substance under federal law, creating fundamental legal uncertainty for Organigram Holdings and all plant-touching cannabis operators. Changes in federal enforcement policy, state regulatory frameworks, or local ordinances could materially impact the company's operations, licensing, and financial performance. The evolving patchwork of state regulations creates compliance complexity and limits the ability to operate across state lines.
Section 280E Tax Burden
Under IRS Section 280E, cannabis businesses are prohibited from deducting ordinary business expenses for federal income tax purposes. This effectively results in tax rates that can exceed 70% of gross profit for plant-touching operators, significantly reducing cash flow available for reinvestment and debt service. While potential rescheduling could eliminate this burden, the timeline and outcome remain uncertain, and Organigram Holdings's profitability metrics should be evaluated with this tax overhang in mind.
Market & Competition Risk
The cannabis industry faces pricing pressure from oversupply in mature markets, competition from the illicit market (which avoids regulatory costs and taxation), and evolving consumer preferences. Organigram Holdings competes for market share against both established operators and well-funded new entrants. Price compression in key markets has squeezed margins across the industry, and any worsening of these trends could materially impact the company's revenue and profitability outlook.
Frequently Asked Questions
Common questions about Organigram Holdings (OGI) stock, answered with real-time data from Cannabismarketcap.
What is Organigram Holdings's (OGI) stock price today?
Organigram Holdings (OGI) stock is currently trading at $0.94 per share on the NASDAQ exchange. This represents a daily decline of -0.43% ($0.0040) from the previous closing price of $0.94. Over the past 52 weeks, OGI has traded between a low of $0.85 and a high of $2.24, placing the current price at approximately -58% from its annual high. The stock has a market capitalization of $131.3M, making it a notable cannabis companies tracked by Cannabismarketcap. Organigram Holdings operates in the LP sector, serving the broader cannabis industry.
What is Organigram Holdings's market capitalization?
Organigram Holdings (OGI) has a current market capitalization of $131.3M, calculated by multiplying its 136.3M shares outstanding by the current stock price of $0.94. Market capitalization is a key measure of a company's total equity value as perceived by the public market, and it places Organigram Holdings among the mid-cap cannabis companies tracked on Cannabismarketcap. Investors often use market cap alongside revenue and profitability metrics to assess relative valuation within the cannabis sector.
What are Organigram Holdings's key financial metrics?
Organigram Holdings (OGI) reports several important financial metrics that investors track closely. The company has a market capitalization of $131.3M. Cash and debt figures for Organigram Holdings are not reported in our data. With 136.3M shares outstanding, investors should consider both the fundamental financial performance and share structure when evaluating OGI.
How many employees does Organigram Holdings have?
Organigram Holdings currently employs approximately 1,139 people across its operations. As a licensed cannabis producer (LP) headquartered in Canada, its workforce supports activities spanning related business functions. Employee count is an important indicator of a company's operational scale and its capacity for growth in an industry that remains highly labor-intensive due to regulatory requirements.
What exchange is OGI listed on?
Organigram Holdings trades under the ticker symbol OGI on the NASDAQ exchange, and the stock is denominated in US dollars (USD). Shares can typically be purchased through most standard brokerage accounts. The company has been publicly listed since 2014-08-27, giving it a track record in the public markets that investors can analyze for long-term trends. The stock sees average daily trading volume of approximately 447.6K shares, which is an important consideration for liquidity and the ability to enter or exit positions without significant price impact.
What sector is Organigram Holdings in?
Organigram Holdings is classified as a licensed cannabis producer (LP), meaning it is a licensed producer of cannabis, typically operating under a national framework for cultivation and distribution. The LP sector is a key segment of the cannabis market, and investors often compare companies within the same sector to identify relative outperformers. You can compare OGI with other LP stocks on Cannabismarketcap's sector page to see how it ranks on metrics like market cap, revenue, and margins.
How does OGI compare to other cannabis stocks?
You can compare Organigram Holdings (OGI) side-by-side with any cannabis stock on Cannabismarketcap using the dedicated comparison tool. Key comparison metrics include market cap ($131.3M). Organigram Holdings sits in the LP sector, so the most relevant peer comparisons would be against other LP companies, though cross-sector comparisons can also reveal interesting insights about relative valuation. Visit the rankings page to see where OGI stands across all cannabis companies on metrics like revenue growth, cash position, and employee count (1,139).
What is OGI's 52-week trading range?
Organigram Holdings (OGI) has traded between a 52-week low of $0.85 and a 52-week high of $2.24, with the current price of $0.94 sitting approximately -58% from the annual high. This range represents a spread of $1.39 (163% from low to high), which reflects the volatility the stock has experienced over the past year. The 52-week range is a commonly used technical indicator that helps investors understand whether a stock is trading near the top or bottom of its recent range, and it can inform decisions about entry and exit points. Cannabis stocks in general tend to exhibit higher volatility than broader market indices due to evolving regulations and market sentiment.
How does Organigram Holdings's valuation compare to cannabis industry peers?
Organigram Holdings (OGI) is valued at a market capitalization of $131.3M. In the cannabis industry, valuations can vary significantly depending on sector (MSO, LP, Ancillary, etc.), growth rate, and path to profitability. Investors can use the Cannabismarketcap rankings and comparison tools to benchmark OGI against specific competitors on valuation multiples, growth rates, and profitability.
Is Organigram Holdings stock overvalued or undervalued?
Determining whether Organigram Holdings (OGI) is overvalued or undervalued requires analyzing multiple valuation metrics in context. The stock is currently trading at $0.94, which is -58% from its 52-week high of $2.24. Investors should consider the broader cannabis industry outlook when forming a valuation opinion. Cannabismarketcap provides all the data needed for a thorough analysis, but this information should not be considered investment advice.
What are the risks of investing in Organigram Holdings?
Investing in Organigram Holdings (OGI) carries several risks that investors should carefully consider. First, the cannabis industry remains federally illegal in the United States, creating regulatory uncertainty that can impact stock prices, banking access, and tax obligations (notably IRC Section 280E). Second, Organigram Holdings's cash and debt levels are not reported in our data, so investors should check its latest filings for liquidity and dilution risk. Additionally, the stock has shown a 52-week range of $0.85 to $2.24, reflecting meaningful price volatility. As with all cannabis stocks, investors face risks from changing state regulations, competitive pressures, and the evolving legal landscape. This information is for educational purposes only and is not investment advice.
How many shares outstanding does Organigram Holdings have?
Organigram Holdings (OGI) currently has 136.3M shares outstanding, which when multiplied by the current stock price of $0.94 gives the company its market capitalization of $131.3M. Share count is important because all per-share metrics (earnings per share, book value per share, etc.) are directly impacted by changes in shares outstanding. Cannabis companies frequently issue new shares to raise capital, so monitoring dilution trends on Cannabismarketcap is recommended for long-term investors.
Does Organigram Holdings pay a dividend?
Most cannabis companies, including Organigram Holdings (OGI), do not currently pay dividends. The cannabis industry is still in a growth phase, and companies typically reinvest available capital into expanding operations, securing new licenses, building out retail and cultivation infrastructure, and navigating complex regulatory requirements. Additionally, the IRC Section 280E tax burden significantly reduces the free cash flow available for shareholder distributions. Investors in cannabis stocks should generally expect returns to come from capital appreciation rather than dividend income. If Organigram Holdings initiates a dividend in the future, it would be reported in their SEC filings and reflected on Cannabismarketcap.
How can I research Organigram Holdings stock before investing?
To research Organigram Holdings (OGI) before investing, start with the company overview on Cannabismarketcap, which provides current price ($0.94), market cap ($131.3M), and key financial metrics. Next, review the full financial statements page for quarterly revenue trends, margins, and balance sheet details. Check the analyst ratings page for Wall Street consensus and price targets, and the technical analysis page for chart patterns and momentum indicators. Compare OGI against sector peers using the comparison tool to understand relative valuation. Review recent news coverage for regulatory developments or corporate events. Finally, read the investment analysis page for a comprehensive deep-dive. Cannabis investing carries unique risks including federal illegality, regulatory uncertainty, and limited banking access — always conduct thorough due diligence before making any investment decision.
What does Organigram Holdings's market cap of $131.3M mean?
Organigram Holdings's market capitalization of $131.3M represents the total market value of all its outstanding shares (136.3M shares multiplied by the current stock price of $0.94). Market cap is the primary measure investors use to classify companies by size: mid-cap companies ($100M–$1B) like Organigram Holdings offer a balance between growth potential and stability. In the cannabis sector, market cap is especially important because it determines index weighting, institutional investment eligibility, and often correlates with the company's operational scale and geographic reach. Organigram Holdings currently ranks # among cannabis stocks tracked on Cannabismarketcap.
What regulatory risks does Organigram Holdings face?
Organigram Holdings (OGI), like all cannabis companies, faces significant regulatory risks that investors should understand. At the federal level, cannabis remains a Schedule I controlled substance in the United States, which restricts banking access, prevents standard business expense deductions under IRC Section 280E, and creates legal uncertainty. As a licensed producer, Organigram Holdings operates under national cannabis frameworks that can change with new government policy, affecting production quotas, export capabilities, and market access. Potential catalysts include federal rescheduling (which could ease 280E burdens), the SAFE Banking Act (which would improve banking access), and individual state legalization events. Conversely, regulatory setbacks such as license moratoriums, increased enforcement, or unfavorable tax policy changes pose downside risks. Investors should monitor legislative developments closely using Cannabismarketcap's news and legalization tracker.
More OGI Research & Data
OGI price, chart & key stats
Revenue, earnings & balance sheet
Quarterly earnings & EPS trends
Historical price & volume chart
Step-by-step buying guide
Side-by-side peer comparison
Detailed investment thesis & outlook
Disclaimer: The information presented on this page is for informational and educational purposes only and does not constitute investment advice, financial advice, trading advice, or any other kind of advice. Cannabismarketcap does not recommend that any security be bought, sold, or held by you. All investments involve risk, and the past performance of a security, industry, sector, market, financial product, trading strategy, or individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. Such decisions should be based solely on an evaluation of their financial circumstances, investment objectives, risk tolerance, and liquidity needs. Cannabis stocks carry additional risks including federal illegality, regulatory uncertainty, limited banking access, and high volatility. Always conduct your own research and consider consulting a qualified financial advisor before making investment decisions.